Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.

Ashok AH, Mizuno Y, Volkow ND, Howes OD.

JAMA Psychiatry. 2017 May 1;74(5):511-519. doi: 10.1001/jamapsychiatry.2017.0135. Review.

2.

Classic Studies on the Interaction of Cocaine and the Dopamine Transporter.

Verma V.

Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):227-38. doi: 10.9758/cpn.2015.13.3.227.

3.

Anhedonia, Reduced Cocaine Reward, and Dopamine Dysfunction in a Rat Model of Posttraumatic Stress Disorder.

Enman NM, Arthur K, Ward SJ, Perrine SA, Unterwald EM.

Biol Psychiatry. 2015 Dec 15;78(12):871-9. doi: 10.1016/j.biopsych.2015.04.024. Epub 2015 May 6.

4.

Psychostimulants and movement disorders.

Asser A, Taba P.

Front Neurol. 2015 Apr 20;6:75. doi: 10.3389/fneur.2015.00075. eCollection 2015. Review.

5.

A Single Amphetamine Infusion Reverses Deficits in Dopamine Nerve-Terminal Function Caused by a History of Cocaine Self-Administration.

Ferris MJ, Calipari ES, Rose JH, Siciliano CA, Sun H, Chen R, Jones SR.

Neuropsychopharmacology. 2015 Jul;40(8):1826-36. doi: 10.1038/npp.2015.45. Epub 2015 Feb 18.

6.

Adaptations of presynaptic dopamine terminals induced by psychostimulant self-administration.

Siciliano CA, Calipari ES, Ferris MJ, Jones SR.

ACS Chem Neurosci. 2015 Jan 21;6(1):27-36. doi: 10.1021/cn5002705. Epub 2014 Dec 26. Review.

7.

Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Howell LL, Negus SS.

Adv Pharmacol. 2014;69:129-76. doi: 10.1016/B978-0-12-420118-7.00004-4. Review.

8.

Pharmacotherapy for stimulant-related disorders.

Haile CN, Kosten TR.

Curr Psychiatry Rep. 2013 Nov;15(11):415. doi: 10.1007/s11920-013-0415-y. Review.

9.

Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice.

Paris JJ, Carey AN, Shay CF, Gomes SM, He JJ, McLaughlin JP.

Neuropsychopharmacology. 2014 Jan;39(2):380-8. doi: 10.1038/npp.2013.201. Epub 2013 Aug 15.

10.

Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels.

Voon V, Rizos A, Chakravartty R, Mulholland N, Robinson S, Howell NA, Harrison N, Vivian G, Ray Chaudhuri K.

J Neurol Neurosurg Psychiatry. 2014 Feb;85(2):148-52. doi: 10.1136/jnnp-2013-305395. Epub 2013 Jul 30.

11.

Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity.

Trifilieff P, Martinez D.

Neuropharmacology. 2014 Jan;76 Pt B:498-509. doi: 10.1016/j.neuropharm.2013.06.031. Epub 2013 Jul 10. Review.

12.

Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence.

Trifilieff P, Martinez D.

Front Psychiatry. 2013 Jun 3;4:44. doi: 10.3389/fpsyt.2013.00044. eCollection 2013.

13.

Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder.

Wang GJ, Volkow ND, Wigal T, Kollins SH, Newcorn JH, Telang F, Logan J, Jayne M, Wong CT, Han H, Fowler JS, Zhu W, Swanson JM.

PLoS One. 2013 May 15;8(5):e63023. doi: 10.1371/journal.pone.0063023. Print 2013.

14.

Recovering from cocaine: insights from clinical and preclinical investigations.

Hanlon CA, Beveridge TJ, Porrino LJ.

Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2037-46. doi: 10.1016/j.neubiorev.2013.04.007. Epub 2013 Apr 27. Review.

15.

Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction.

Sullivan D, Pinsonneault JK, Papp AC, Zhu H, Lemeshow S, Mash DC, Sadee W.

Transl Psychiatry. 2013 Jan 22;3:e222. doi: 10.1038/tp.2012.146.

16.

Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.

Shen LH, Liao MH, Tseng YC.

J Biomed Biotechnol. 2012;2012:259349. doi: 10.1155/2012/259349. Epub 2012 Apr 10. Review.

17.

Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Haile CN, Mahoney JJ 3rd, Newton TF, De La Garza R 2nd.

Pharmacol Ther. 2012 May;134(2):260-77. doi: 10.1016/j.pharmthera.2012.01.010. Epub 2012 Jan 31. Review.

18.

In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA, Daley DC, Price JC, Mathis CA, Frankle WG.

Am J Psychiatry. 2012 Jan;169(1):55-63. doi: 10.1176/appi.ajp.2011.11010126. Epub 2011 Oct 31.

19.

Excited delirium.

Takeuchi A, Ahern TL, Henderson SO.

West J Emerg Med. 2011 Feb;12(1):77-83.

20.

Neuroimaging and drug taking in primates.

Murnane KS, Howell LL.

Psychopharmacology (Berl). 2011 Jul;216(2):153-71. doi: 10.1007/s00213-011-2222-7. Epub 2011 Mar 1. Review.

Supplemental Content

Support Center